序号股票简称PE(TTM)PE(静)市净率总市值(元)11安杰思17.5917.802.1352.22亿行业平均 52.0649.724.58107.83亿行业中值37.2238.112.4752.18亿1九安医疗10.3010.410.81173.78亿2英科医疗 10.8811.730.97171.88亿3新华医疗14.4413.391.1892.58亿4振德医疗15.4114.530.9855.95亿5奥美医疗 15.5115.201.5956.04亿6山东药玻15.6115.661.79147.65亿7康德莱16.0916.111.3334.68亿8维力医疗 16.6017.261.9537.87亿9奥泰生物16.6317.541.3453.04亿10九强生物16.7915.612.0683.13亿12三鑫医疗 18.9718.983.1243.15亿 7月11日，安杰思今日收盘64.49元，上涨1.08%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到17.59倍，总市值52.22亿元。 来源：金融界 杭州安杰思医学科技股份有限公司的主营业务是内镜微创诊疗器械的研发、生产与销售。公司的 ...

7月4日，南微医学今日收盘70.52元，上涨3.46%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到23.21倍，创87天以来新低，总市值132.47亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.05倍，行业中值36.62倍，南微医学排 名第50位。 股东方面，截至2025年3月31日，南微医学股东户数13313户，较上次增加639户，户均持股市值35.28万 元，户均持股数量2.76万股。 南微医学科技股份有限公司的主营业务是微创医疗器械的研发、制造和销售。公司的主要产品是活检 类、止血和闭合类、EMR/ESD类、扩张类、ERCP类、EUS/EBUS类、消融仪、消融针系列产品、一次 性胆胰成像系统（胆道镜）、一次性支气管镜及相关耗材。 最新一期业绩显示，2025年一季报，公司实现营业收入6.99亿元，同比12.75%；净利润1.61亿元，同比 12.18%，销售毛利率65.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13南微医学23.2123.943.32132.47亿行业平均 51.0548.784.55107.12亿行业中值36.6236.522 ...

7月1日，安杰思今日收盘67.86元，上涨4.67%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到18.51倍，创59天以来新低，总市值54.95亿元。 杭州安杰思医学科技股份有限公司的主营业务是内镜微创诊疗器械的研发、生产与销售。公司的主要产 品是GI类、EMR/ESD类、ERCP诊疗系列、诊疗仪器设备。报告期内，公司取得重要政府荣誉7项，获 得"浙江省级企业技术中心"、"浙江省生物医药高成长型企业"、"浙江省首批两新重大科技成果"、"杭 州市绿色工厂"、"杭州市优质产品（止血夹）2023年杭州市总部企业"等荣誉。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.70倍，行业中值37.36倍，安杰思排名 第41位。 截至2025年一季报，共有11家机构持仓安杰思，其中基金6家、其他5家，合计持股数1773.25万股，持 股市值12.60亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)11安杰思18.5118.732.2454.95亿行业平均 51.7049.814.63107.66亿行业中值37.3638.092.4550.67亿1英科医疗9.9710.750.89 ...

7月1日，南微医学今日收盘69.64元，上涨3.09%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到22.92倍，创60天以来新低，总市值130.82亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.70倍，行业中值37.36倍，南微医学排 名第49位。 截至2025年一季报，共有17家机构持仓南微医学，其中基金11家、其他4家、社保2家，合计持股数 10647.33万股，持股市值70.17亿元。 南微医学科技股份有限公司的主营业务是微创医疗器械的研发、制造和销售。公司的主要产品是活检 类、止血和闭合类、EMR/ESD类、扩张类、ERCP类、EUS/EBUS类、消融仪、消融针系列产品、一次 性胆胰成像系统（胆道镜）、一次性支气管镜及相关耗材。 最新一期业绩显示，2025年一季报，公司实现营业收入6.99亿元，同比12.75%；净利润1.61亿元，同比 12.18%，销售毛利率65.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13南微医学22.9223.653.27130.82亿行业平均 51.7049.814.63107.66亿行业中值37.3638.09 ...

6月26日，南微医学今日收盘66.93元，上涨2.18%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到22.03倍，总市值125.73亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.45倍，行业中值35.92倍，南微医学排 名第49位。 截至2025年一季报，共有17家机构持仓南微医学，其中基金11家、其他4家、社保2家，合计持股数 10647.33万股，持股市值70.17亿元。 南微医学科技股份有限公司的主营业务是微创医疗器械的研发、制造和销售。公司的主要产品是活检 类、止血和闭合类、EMR/ESD类、扩张类、ERCP类、EUS/EBUS类、消融仪、消融针系列产品、一次 性胆胰成像系统（胆道镜）、一次性支气管镜及相关耗材。 最新一期业绩显示，2025年一季报，公司实现营业收入6.99亿元，同比12.75%；净利润1.61亿元，同比 12.18%，销售毛利率65.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13南微医学22.0322.733.15125.73亿行业平均 49.4547.484.57105.42亿行业中值35.9237.582.3948.6 ...

杭州安杰思医学科技股份有限公司的主营业务是内镜微创诊疗器械的研发、生产与销售。公司的主要产 品是GI类、EMR/ESD类、ERCP诊疗系列、诊疗仪器设备。报告期内，公司取得重要政府荣誉7项，获 得"浙江省级企业技术中心"、"浙江省生物医药高成长型企业"、"浙江省首批两新重大科技成果"、"杭 州市绿色工厂"、"杭州市优质产品（止血夹）2023年杭州市总部企业"等荣誉。 最新一期业绩显示，2025年一季报，公司实现营业收入1.29亿元，同比15.27%；净利润5624.83万元， 同比6.57%，销售毛利率70.68%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)11安杰思17.2317.442.0851.16亿行业平均 49.1247.184.49104.96亿行业中值36.0737.112.4149.03亿1英科医疗9.6910.450.86153.16亿2九安医疗 10.1410.250.80171.07亿3新华医疗14.2913.251.1791.61亿4奥美医疗15.1114.811.5554.59亿5康德莱 15.2015.211.2632.76亿6振德医疗15.4114.520.9855 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Nanwei Medical, which closed at 65.28 yuan with a PE ratio of 21.49 and a total market capitalization of 12.263 billion yuan [1][2] - The average PE ratio for the medical device industry is 49.12, with a median of 36.07, positioning Nanwei Medical at the 49th rank within the industry [1][2] - As of March 31, 2025, the number of shareholders for Nanwei Medical increased to 13,313, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Nanwei Medical specializes in the research, manufacturing, and sales of minimally invasive medical devices, with key products including biopsy, hemostasis, closure devices, EMR/ESD devices, dilation devices, ERCP devices, EUS/EBUS devices, ablation instruments, disposable imaging systems, and related consumables [1] - In the latest quarterly report for Q1 2025, the company reported a revenue of 699 million yuan, reflecting a year-on-year growth of 12.75%, and a net profit of 161 million yuan, also showing a year-on-year increase of 12.18%, with a gross margin of 65.69% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Nanwei Medical, which has a current stock price of 65.72 yuan and a market capitalization of 12.345 billion yuan, with a rolling PE ratio of 21.63 times [1] - The medical device industry has an average PE ratio of 49.56 times and a median of 36.18 times, placing Nanwei Medical at the 49th position in the industry ranking [1][2] - As of the first quarter of 2025, 17 institutions hold shares in Nanwei Medical, including 11 funds, with a total shareholding of 106.4733 million shares valued at 7.017 billion yuan [1] Group 2 - Nanwei Medical specializes in the research, development, manufacturing, and sales of minimally invasive medical devices, with key products including biopsy, hemostasis, EMR/ESD, dilation, ERCP, EUS/EBUS devices, ablation instruments, disposable imaging systems, and related consumables [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 699 million yuan, a year-on-year increase of 12.75%, and a net profit of 161 million yuan, also reflecting a year-on-year increase of 12.18%, with a gross profit margin of 65.69% [1]

6月10日，安杰思今日收盘64.97元，上涨1.83%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到17.72倍，创12天以来新低，总市值52.61亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.00倍，行业中值37.03倍，安杰思排名 第41位。 截至2025年一季报，共有11家机构持仓安杰思，其中基金6家、其他5家，合计持股数1773.25万股，持 股市值12.60亿元。 杭州安杰思医学科技股份有限公司的主营业务是内镜微创诊疗器械的研发、生产与销售。公司的主要产 品是GI类、EMR/ESD类、ERCP诊疗系列、诊疗仪器设备。报告期内，公司取得重要政府荣誉7项，获 得"浙江省级企业技术中心"、"浙江省生物医药高成长型企业"、"浙江省首批两新重大科技成果"、"杭 州市绿色工厂"、"杭州市优质产品（止血夹）2023年杭州市总部企业"等荣誉。 最新一期业绩显示，2025年一季报，公司实现营业收入1.29亿元，同比15.27%；净利润5624.83万元， 同比6.57%，销售毛利率70.68%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)41安杰思17.7217.93 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anjisi Medical Technology Co., Ltd., which operates in the medical device industry, specifically focusing on minimally invasive endoscopic diagnostic and therapeutic instruments [1][2] - As of May 29, Anjisi's closing stock price was 64.92 yuan, reflecting a 1.41% increase, with a rolling price-to-earnings (PE) ratio of 17.71 times and a total market capitalization of 5.257 billion yuan [1] - The average PE ratio for the medical device industry is 49.64 times, with a median of 36.36 times, positioning Anjisi at the 41st rank within the industry [1][2] Group 2 - As of the first quarter of 2025, 11 institutions held shares in Anjisi, including 6 funds and 5 other entities, with a total holding of 17.7325 million shares valued at 1.26 billion yuan [1] - Anjisi's main business involves the research, production, and sales of endoscopic minimally invasive diagnostic and therapeutic instruments, with key products including GI, EMR/ESD, and ERCP diagnostic series [1] - In the latest quarterly report, Anjisi reported a revenue of 129 million yuan, representing a year-on-year increase of 15.27%, and a net profit of 56.2483 million yuan, with a year-on-year growth of 6.57%, and a gross profit margin of 70.68% [1]